[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" css=".vc_custom_1553053145064{padding-top: 30px !important;padding-bottom: 30px !important;}" z_index=""][vc_column][vc_single_image image="16599" img_size="large" alignment="center" qode_css_animation=""][/vc_column][/vc_row][vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] Sponsored by: [/vc_column_text][vc_single_image image="16544" img_size="large" alignment="center" qode_css_animation=""][/vc_column][/vc_row][vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] Join us on June 27, 2019 for a day...

Article originally appeared on sciencedaily.com, November 7, 2017. In a recent paper published in the journal Skeletal Muscle, a Saint Louis University researcher reports success in identifying new drug targets that potentially could slow or halt the progression of a form muscular dystrophy, an illness characterized by progressive muscle...

Article originally appeared on musculardystrophynews.com, October 10, 2017. Resolaris (ATYR1940) improved the muscle strength of nearly two-thirds of adolescents and young adults with early-onset facioscapulohumeral muscular dystrophy (FSHD), according to final results of a Phase 1/2 clinical trial. The therapy’s maker, aTyr Pharma, presented the findings at the 22nd International Annual Congress of the World Muscle Society...

    Post by Chris Carrino June 20th is World FSHD Day. A day of awareness for FSHD, to show we are united for a cure. However, for those of us affected by this disease, June 20th is simply known as  - Tuesday. There isn’t a moment of every day that...